Back to top

Why the Earnings Surprise Streak Could Continue for Myriad (MYGN)

Read MoreHide Full Article

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Myriad Genetics (MYGN - Free Report) , which belongs to the Zacks Medical - Biomedical and Genetics industry.

This molecular diagnostic company has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 29.24%.

For the last reported quarter, Myriad came out with earnings of $0.43 per share versus the Zacks Consensus Estimate of $0.30 per share, representing a surprise of 43.33%. For the previous quarter, the company was expected to post earnings of $0.33 per share and it actually produced earnings of $0.38 per share, delivering a surprise of 15.15%.

Price and EPS Surprise

Thanks in part to this history, there has been a favorable change in earnings estimates for Myriad lately. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the stock is positive, which is a great indicator of an earnings beat, particularly when combined with its solid Zacks Rank.

Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Myriad currently has an Earnings ESP of +17.65%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #1 (Strong Buy) indicates that another beat is possibly around the corner. We expect the company's next earnings report to be released on February 5, 2019.

When the Earnings ESP comes up negative, investors should note that this will reduce the predictive power of the metric. But, a negative value is not indicative of a stock's earnings miss.

Many companies end up beating the consensus EPS estimate, though this is not the only reason why their shares gain. Additionally, some stocks may remain stable even if they end up missing the consensus estimate.

Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Myriad Genetics, Inc. (MYGN) - free report >>

More from Zacks Tale of the Tape

You May Like

Published in